Italia markets close in 5 hours 55 minutes
FTSE MIB
34.448,17 -211,38 (-0,61%) Dow Jones
38.852,86 -216,74 (-0,55%) Nasdaq
17.019,88 +99,08 (+0,59%) Nikkei 225
38.556,87 -298,50 (-0,77%) Petrolio
80,53 +0,70 (+0,88%) Bitcoin EUR
62.389,18 -380,93 (-0,61%)
NVCR Jan 2026 20.000 put
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 03:30PM EDT. Mercato aperto.
| Chiusura precedente | 5,20 |
| Aperto | 9,90 |
| Denaro | 0,00 |
| Domanda | 0,00 |
| Prezzo d'esercizio | 20,00 |
| Scadenza | 2026-01-16 |
| Min-Max giorno | 5,20 - 9,90 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | N/D |
GlobeNewswireZai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in
© 2024 Yahoo. Tutti i diritti riservati.